Summary of Key Information:
Reporting Period (Quarter/Year): Financial Year 2025-26
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Audit Opinion:
Not Specified
Auditor’s Comment:
Not Specified
Key Financial Highlights:
Not Specified
Standalone Results:
Not Specified
Consolidated Results:
Not Specified
Segment-wise Performance:
Not Specified
Corporate Actions:
Dividend:
- The Board of Directors recommended a final dividend of ₹1.50 per equity share (face value ₹1/- each fully paid-up) for the financial year ended March 31, 2026.
- The record date for determining members eligible for the dividend is fixed as Friday, August 7, 2026.
- The dividend, subject to members' approval at the 27th Annual General Meeting and deduction of tax at source, will be paid within 30 days from the date of approval.
- The payment will be made to members and beneficial owners whose names are recorded in the Register of Members or depository records as of the close of business hours on August 7, 2026.
Merger:
- The Board approved the Scheme of Merger for Kia Health Tech Private Limited (a wholly owned subsidiary) with Rubicon Research Limited under Section 233 of the Companies Act, 2013.
- The Appointed Date under the Scheme is April 1, 2026.
- Since Kia Health Tech is a wholly owned subsidiary, no shares of Rubicon Research Limited will be issued, and no consideration will be payable pursuant to the Scheme.
- There will be no change in the shareholding pattern or voting rights of the Company as a result of this merger.
- The Scheme remains subject to statutory, regulatory, shareholder, and creditor approvals as required by law.
Other Significant Information:
Company Identification: